Alliance Pharma (APH)
APH Share PerformanceMore
|52 week high||62.75 08/11/17|
|52 week low||41.79 23/12/16|
|52 week change||13.25 (29.61%)|
|4 week volume||9,669,548 23/10/17|
Latest News« previous» nextMore
17/10/2017 - 08:45 StockMarketWire
Hardman Research has issued a report noting that Alliance Pharma's Kelo-cote brand is building international sales. Hardm...
17/10/2017 - 08:14 RNS
RNS Number: 7998T Alliance Pharma PLC 17 October 2017 Hardman Research: Kelo-cote building international sales Kelo-cote building international sales - Alliance Pharma's buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma ha...
13/09/2017 - 06:52 StockMarketWire
Alliance Pharma's revenues rose by 8% to 50.3m in the six months to the end of June. EBITDA increased by 3% to 13.6m an...
13/09/2017 - 06:00 RNS
RNS Number: 5694Q Alliance Pharma PLC 13 September 2017 For immediate release 13 September 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Interim Results for the six months ended 30 June 2017 Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce its interim results for the six months ended 30 June ...
06/09/2017 - 06:00 RNS
RNS Number: 9074P Alliance Pharma PLC 06 September 2017 For immediate release 6 September 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Appointment of Joint Corporate Broker Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce the appointment of Investec Bank plc as joint corporate broker to ...
01/08/2017 - 06:00 RNS
RNS Number: 6570M Alliance Pharma PLC 01 August 2017 For immediate release 1 August 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Notification of Interim Results Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2017 on Wednesday 13 September 201...
31/07/2017 - 08:00 StockMarketWire
finnCap today reaffirms its buy investment rating on Alliance Pharma PLC (LON:APH) and cut its price target to 58p (fr...
28/07/2017 - 15:21 RNS
RNS Number: 4885M Alliance Pharma PLC 28 July 2017 For immediate release 28 July 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Update on Diclectin Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that it has been advised by the UK's regulator, the Medicines and Healthcare products Regulatory Agency (M...
|Dividend yield||2.086 %|
Latest discussion posts More
“Hard to tell, perhaps a largish holder off-loading. For all that, could be up again today. ws”▼
“Volume is also high, so somethings abound..no idea what it may be.”▼
“Does anyone know of a good reason for today's retrace? I am tempted to top up once more. ws”▼
Codes & Symbols
|Symbols||APH, LSE:APH, APH.L, APH:LN, LON:APH, XLON:APH|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment